| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | AN | AO | AP | AQ | AR | AS | AT | AU | AV | AW | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | New Incentives – current states of operation | New Incentives – prospective states | New Incentives – prospective states | |||||||||||||||||||||||||||||||||||||||||||||||
2 | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | Nigeria | ||||||||||
3 | Main calculations | unit | type | Overall | Bauchi | Gombe | Jigawa | Kaduna - cohort 17 | Kano | Katsina | Kebbi | Sokoto | Zamfara | Abia | Adamawa | Akwa Ibom | Anambra | Bayelsa | Benue | Borno | Cross River | Delta | Ebonyi | Edo | Ekiti | Enugu | FCT | Imo | Kaduna | Kogi | Kwara | Lagos | Nasarawa | Niger | Niger - cohorts 32 & 36 | Niger - cohort 34 | Ogun | Ondo | Osun | Oyo | Plateau | Rivers | Taraba | Yobe | ||||||
4 | Final cost-effectiveness estimate (pulled from "Main calcs" sheet for visibility) | xcash | calc | - | 21.4 | 10.8 | 19.5 | 9.7 | 13.3 | 17.8 | 31.4 | 41.5 | 32.7 | 1.8 | 4.1 | 1.7 | 1.9 | 2.7 | 3.1 | 5.1 | 1.5 | 2.2 | 1.1 | 1.6 | 1.2 | 1.1 | 1.5 | 1.2 | 5.5 | 2.2 | 2.1 | 1.1 | 3.4 | 7.8 | 9.5 | 5.5 | 2.6 | 2.4 | 1.2 | 1.8 | 2.3 | 1.6 | 6.6 | 11.5 | ||||||
5 | Baseline coverage for the target population | |||||||||||||||||||||||||||||||||||||||||||||||||
6 | ||||||||||||||||||||||||||||||||||||||||||||||||||
7 | Baseline vaccination coverage for the target population | |||||||||||||||||||||||||||||||||||||||||||||||||
8 | Baseline proportion of children in the target population who receive the BCG vaccine | % | supp | - | 55% | 72% | 61% | 63% | 63% | 49% | 39% | 35% | 48% | 91% | 89% | 86% | 84% | 79% | 82% | 65% | 93% | 84% | 99% | 92% | 99% | 99% | 95% | 95% | 77% | 92% | 72% | 94% | 79% | 67% | 62% | 77% | 72% | 75% | 93% | 83% | 88% | 90% | 76% | 65% | ||||||
9 | Baseline proportion of children in the target population who receive the 1st dose of the Penta vaccine | % | supp | - | 49% | 67% | 57% | 59% | 58% | 46% | 32% | 27% | 42% | 88% | 86% | 86% | 83% | 78% | 81% | 58% | 93% | 81% | 99% | 92% | 95% | 99% | 91% | 94% | 74% | 86% | 66% | 92% | 72% | 63% | 57% | 75% | 67% | 73% | 91% | 76% | 80% | 90% | 73% | 61% | ||||||
10 | Baseline proportion of children in the target population who receive the 2nd dose of the Penta vaccine | % | supp | - | 45% | 63% | 51% | 50% | 50% | 42% | 23% | 25% | 33% | 86% | 79% | 82% | 75% | 76% | 75% | 45% | 92% | 76% | 99% | 91% | 94% | 97% | 87% | 93% | 67% | 74% | 64% | 90% | 65% | 52% | 45% | 65% | 58% | 68% | 88% | 64% | 78% | 87% | 67% | 52% | ||||||
11 | Baseline proportion of children in the target population who receive the 3rd dose of the Penta vaccine | % | supp | - | 36% | 50% | 39% | 41% | 38% | 35% | 14% | 18% | 23% | 75% | 70% | 73% | 74% | 70% | 63% | 30% | 75% | 70% | 99% | 83% | 85% | 91% | 80% | 89% | 58% | 63% | 55% | 85% | 54% | 39% | 33% | 50% | 41% | 63% | 82% | 57% | 65% | 78% | 56% | 42% | ||||||
12 | Baseline proportion of children in the target population who receive the 1st dose of the PCV vaccine | % | supp | - | 49% | 63% | 56% | 58% | 56% | 44% | 32% | 21% | 43% | 89% | 86% | 84% | 83% | 77% | 79% | 54% | 93% | 79% | 99% | 90% | 96% | 99% | 91% | 94% | 72% | 85% | 64% | 92% | 71% | 61% | 55% | 73% | 65% | 72% | 91% | 75% | 79% | 90% | 71% | 60% | ||||||
13 | Baseline proportion of children in the target population who receive the 2nd dose of the PCV vaccine | % | supp | - | 45% | 60% | 51% | 50% | 48% | 40% | 23% | 20% | 33% | 85% | 79% | 82% | 75% | 75% | 71% | 38% | 92% | 73% | 99% | 86% | 90% | 96% | 87% | 91% | 65% | 72% | 61% | 89% | 63% | 50% | 44% | 64% | 57% | 66% | 83% | 63% | 69% | 85% | 65% | 51% | ||||||
14 | Baseline proportion of children in the target population who receive the 3rd dose of the PCV vaccine | % | supp | - | 36% | 47% | 39% | 41% | 37% | 34% | 14% | 14% | 25% | 67% | 70% | 71% | 74% | 67% | 56% | 31% | 73% | 69% | 99% | 77% | 83% | 91% | 80% | 86% | 57% | 62% | 53% | 80% | 51% | 38% | 32% | 48% | 40% | 61% | 69% | 57% | 61% | 79% | 54% | 41% | ||||||
15 | Baseline proportion of children in the target popullation who receive the 1st dose of the rotavirus vaccine | % | supp | - | 49% | 65% | 57% | 59% | 57% | 45% | 32% | 24% | 42% | 89% | 86% | 85% | 83% | 77% | 80% | 56% | 93% | 80% | 99% | 91% | 95% | 99% | 91% | 94% | 73% | 85% | 65% | 92% | 71% | 62% | 56% | 74% | 66% | 73% | 91% | 75% | 79% | 90% | 72% | 61% | ||||||
16 | Estimated proportion of children in the target population who receive the 2nd dose of the rotavirus vaccine | % | supp | - | 45% | 61% | 51% | 50% | 49% | 41% | 23% | 22% | 33% | 86% | 79% | 82% | 75% | 76% | 73% | 42% | 92% | 74% | 99% | 88% | 92% | 96% | 87% | 92% | 66% | 73% | 62% | 89% | 64% | 51% | 44% | 64% | 57% | 67% | 86% | 63% | 73% | 86% | 66% | 51% | ||||||
17 | Baseline proportion of children in the target population who receive the 1st dose of the measles vaccine | % | supp | - | 31% | 37% | 56% | 57% | 41% | 44% | 63% | 19% | 46% | 75% | 61% | 72% | 67% | 66% | 68% | 39% | 80% | 73% | 92% | 80% | 95% | 80% | 90% | 75% | 57% | 72% | 64% | 86% | 57% | 55% | 55% | 55% | 56% | 66% | 80% | 61% | 70% | 85% | 65% | 71% | ||||||
18 | ||||||||||||||||||||||||||||||||||||||||||||||||||
19 | Proportion of vaccine-preventable mortalities that could be prevented by each vaccine dose | |||||||||||||||||||||||||||||||||||||||||||||||||
20 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the BCG vaccine | % | feed | - | 21% | 15% | 25% | 14% | 16% | 22% | 21% | 21% | 26% | 12% | 17% | 11% | 11% | 10% | 14% | 13% | 13% | 13% | 15% | 13% | 16% | 13% | 14% | 13% | 14% | 10% | 11% | 12% | 15% | 15% | 15% | 15% | 11% | 12% | 14% | 9% | 16% | 13% | 14% | 22% | ||||||
21 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 1st dose of the Penta vaccine | % | supp | - | 5% | 7% | 6% | 8% | 6% | 7% | 8% | 6% | 6% | 6% | 6% | 7% | 8% | 9% | 6% | 8% | 8% | 7% | 7% | 7% | 6% | 8% | 7% | 7% | 8% | 13% | 8% | 7% | 8% | 7% | 7% | 7% | 8% | 6% | 8% | 9% | 6% | 7% | 6% | 8% | ||||||
22 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 2nd dose of the Penta vaccine | % | supp | - | 8% | 11% | 10% | 12% | 9% | 10% | 12% | 10% | 10% | 9% | 9% | 12% | 13% | 14% | 10% | 13% | 12% | 11% | 11% | 10% | 9% | 13% | 10% | 10% | 12% | 20% | 13% | 11% | 12% | 11% | 11% | 11% | 12% | 9% | 12% | 15% | 10% | 10% | 9% | 12% | ||||||
23 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 3rd dose of the Penta vaccine | % | supp | - | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 4% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 2% | 2% | 2% | 2% | ||||||
24 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 1st dose of the PCV vaccine | % | supp | - | 12% | 14% | 11% | 15% | 14% | 11% | 11% | 11% | 9% | 17% | 15% | 16% | 18% | 13% | 14% | 10% | 16% | 17% | 16% | 18% | 17% | 16% | 17% | 18% | 15% | 13% | 15% | 17% | 15% | 14% | 14% | 14% | 16% | 18% | 15% | 15% | 15% | 17% | 15% | 11% | ||||||
25 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 2nd dose of the PCV vaccine | % | supp | - | 19% | 21% | 18% | 23% | 23% | 17% | 17% | 17% | 14% | 27% | 24% | 26% | 28% | 21% | 22% | 16% | 25% | 26% | 26% | 29% | 27% | 25% | 27% | 29% | 23% | 20% | 23% | 27% | 23% | 21% | 21% | 21% | 25% | 28% | 24% | 24% | 24% | 27% | 24% | 17% | ||||||
26 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 3rd dose of the PCV vaccine | % | supp | - | 3% | 4% | 3% | 4% | 4% | 3% | 3% | 3% | 3% | 5% | 4% | 5% | 5% | 4% | 4% | 3% | 4% | 5% | 5% | 5% | 5% | 5% | 5% | 5% | 4% | 4% | 4% | 5% | 4% | 4% | 4% | 4% | 4% | 5% | 4% | 4% | 4% | 5% | 4% | 3% | ||||||
27 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 1st dose of the rotavirus vaccine | % | supp | - | 20% | 19% | 14% | 14% | 19% | 18% | 17% | 20% | 20% | 18% | 18% | 13% | 9% | 18% | 21% | 23% | 12% | 13% | 13% | 10% | 12% | 11% | 12% | 11% | 14% | 9% | 13% | 13% | 14% | 18% | 18% | 18% | 15% | 13% | 13% | 12% | 16% | 12% | 19% | 14% | ||||||
28 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 2nd dose of the rotavirus vaccine | % | supp | - | 4% | 3% | 2% | 3% | 3% | 3% | 3% | 4% | 3% | 3% | 3% | 2% | 2% | 3% | 4% | 4% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 2% | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 2% | 2% | 2% | 3% | 2% | 3% | 3% | ||||||
29 | Proportion of vaccine-preventable mortalities among people under age 5 that could be prevented by the 1st dose of the measles vaccine | % | supp | - | 6% | 5% | 7% | 5% | 3% | 8% | 8% | 6% | 7% | 2% | 3% | 5% | 3% | 6% | 4% | 8% | 5% | 4% | 4% | 4% | 6% | 4% | 4% | 3% | 5% | 5% | 9% | 5% | 5% | 5% | 5% | 5% | 5% | 5% | 6% | 6% | 5% | 4% | 4% | 8% | ||||||
30 | ||||||||||||||||||||||||||||||||||||||||||||||||||
31 | Baseline vaccination coverage for the target population, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
32 | Proportion of children in the target population who would be vaccinated in the absence of the program, aggregated across vaccines | % | calc | - | 47% | 62% | 55% | 55% | 53% | 44% | 32% | 25% | 40% | 86% | 82% | 82% | 79% | 76% | 76% | 50% | 91% | 77% | 99% | 88% | 93% | 96% | 89% | 92% | 69% | 79% | 64% | 90% | 68% | 57% | 51% | 68% | 61% | 69% | 87% | 69% | 76% | 87% | 69% | 59% | ||||||
33 | Proportion of children in the target population who would not be vaccinated in the absence of the program, aggregated across vaccines - in year of baseline measurement | % | calc | 53% | 38% | 45% | 45% | 47% | 56% | 68% | 75% | 60% | 14% | 18% | 18% | 21% | 24% | 24% | 50% | 9% | 23% | 1% | 12% | 7% | 4% | 11% | 8% | 31% | 21% | 36% | 10% | 32% | 43% | 49% | 32% | 39% | 31% | 13% | 31% | 24% | 13% | 31% | 41% | |||||||
34 | Effective year of baseline measurement | # | supp | 2022 | 2022.5 | 2021.5 | 2023 | 2022.5 | 2021.3 | 2023 | 2021.9 | 2021.1 | 2021 | 2023 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2023 | 2021 | 2021 | 2021 | 2021 | 2024 | 2024 | 2024 | 2021 | 2021 | 2021 | 2021 | 2021 | 2021 | 2022.7 | 2023.6 | |||||||
35 | Counterfactual change in the proportion of unvaccinated children per year in the absence of New Incentives | % | input | -5% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
36 | Middle year of grant period | # | input | 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
37 | Proportion of children in the target population who would not be vaccinated in the absence of the program, aggregated across vaccines - in middle year of grant period | % | calc | 43% | 32% | 36% | 39% | 39% | 44% | 58% | 61% | 46% | 11% | 15% | 14% | 17% | 19% | 19% | 39% | 7% | 18% | 1% | 9% | 5% | 3% | 8% | 6% | 27% | 17% | 28% | 8% | 25% | 39% | 44% | 28% | 30% | 24% | 10% | 24% | 18% | 10% | 26% | 37% | |||||||
38 | Proportion of children in the target population who would be vaccinated in the absence of the program, aggregated across vaccines - in middle year of grant period | % | calc | 57% | 68% | 64% | 61% | 61% | 56% | 42% | 39% | 54% | 89% | 85% | 86% | 83% | 81% | 81% | 61% | 93% | 82% | 99% | 91% | 95% | 97% | 92% | 94% | 73% | 83% | 72% | 92% | 75% | 61% | 56% | 72% | 70% | 76% | 90% | 76% | 82% | 90% | 74% | 63% | |||||||
39 | ||||||||||||||||||||||||||||||||||||||||||||||||||
40 | Vaccine efficacy and coverage for people under age 5, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
41 | ||||||||||||||||||||||||||||||||||||||||||||||||||
42 | Vaccine efficacy with universal coverage | |||||||||||||||||||||||||||||||||||||||||||||||||
43 | BCG vaccine efficacy rate with universal coverage | % | supp | 72% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
44 | DTP vaccine efficacy rate with universal coverage (part of the Penta vaccine) | % | supp | 71% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
45 | Hib vaccine efficacy rate with universal coverage (part of the Penta vaccine) | % | supp | 70% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
46 | PCV vaccine efficacy rate with universal coverage | % | supp | 49% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
47 | Rotavirus vaccine efficacy rate with universal coverage | % | supp | 39% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
48 | Measles vaccine efficacy rate with universal coverage | % | supp | 67% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
49 | ||||||||||||||||||||||||||||||||||||||||||||||||||
50 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by each vaccine, adjusted for deaths occurring before the age of vaccination | |||||||||||||||||||||||||||||||||||||||||||||||||
51 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the BCG vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 16% | 11% | 19% | 11% | 12% | 16% | 16% | 16% | 19% | 8% | 12% | 8% | 8% | 7% | 10% | 10% | 10% | 10% | 11% | 10% | 12% | 10% | 11% | 10% | 11% | 8% | 8% | 9% | 11% | 11% | 11% | 11% | 8% | 9% | 10% | 7% | 11% | 10% | 10% | 17% | ||||||
52 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the DTP vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 9% | 12% | 12% | 13% | 10% | 12% | 14% | 11% | 12% | 7% | 8% | 12% | 14% | 15% | 9% | 15% | 13% | 11% | 10% | 9% | 7% | 14% | 10% | 9% | 13% | 26% | 15% | 10% | 13% | 12% | 12% | 12% | 13% | 9% | 12% | 17% | 10% | 10% | 9% | 15% | ||||||
53 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the Hib vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 2% | 3% | 3% | 4% | 3% | 2% | 2% | 2% | 2% | 2% | 3% | 4% | 4% | 3% | 3% | 2% | 4% | 4% | 5% | 5% | 5% | 5% | 5% | 5% | 4% | 3% | 3% | 5% | 3% | 3% | 3% | 3% | 4% | 4% | 4% | 4% | 4% | 5% | 3% | 3% | ||||||
54 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the PCV vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 36% | 41% | 37% | 46% | 44% | 34% | 34% | 34% | 28% | 50% | 46% | 51% | 56% | 41% | 42% | 31% | 49% | 52% | 50% | 57% | 53% | 51% | 54% | 56% | 46% | 42% | 46% | 53% | 46% | 41% | 41% | 41% | 48% | 55% | 48% | 48% | 46% | 53% | 45% | 34% | ||||||
55 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the rotavirus vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 32% | 30% | 24% | 23% | 29% | 29% | 27% | 32% | 32% | 28% | 28% | 20% | 15% | 29% | 33% | 36% | 20% | 21% | 21% | 17% | 19% | 17% | 19% | 17% | 23% | 16% | 21% | 20% | 23% | 29% | 29% | 29% | 23% | 20% | 21% | 19% | 25% | 19% | 29% | 24% | ||||||
56 | Proportion of deaths from vaccine-preventable causes among unvaccinated people under age 5 that are addressable by the measles vaccine, adjusted for deaths occurring before the age of vaccination | % | supp | - | 5% | 4% | 6% | 4% | 3% | 7% | 7% | 5% | 6% | 2% | 3% | 4% | 3% | 5% | 3% | 6% | 4% | 3% | 3% | 3% | 4% | 4% | 3% | 3% | 4% | 4% | 7% | 4% | 4% | 4% | 4% | 4% | 4% | 4% | 5% | 5% | 4% | 3% | 3% | 7% | ||||||
57 | ||||||||||||||||||||||||||||||||||||||||||||||||||
58 | Vaccine efficacy for people under age 5, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
59 | Proportion of vaccine-preventable disease incidence averted by full vaccination among people under age 5, aggregated across vaccines | % | calc | - | 53% | 53% | 55% | 54% | 52% | 54% | 55% | 53% | 55% | 50% | 52% | 53% | 54% | 53% | 51% | 53% | 54% | 53% | 53% | 53% | 54% | 54% | 53% | 53% | 54% | 57% | 54% | 53% | 54% | 53% | 53% | 53% | 53% | 53% | 54% | 54% | 53% | 53% | 52% | 56% | ||||||
60 | ||||||||||||||||||||||||||||||||||||||||||||||||||
61 | Vaccine coverage for populations under age 5 represented by GBD 2021, aggregated across doses | |||||||||||||||||||||||||||||||||||||||||||||||||
62 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the BCG vaccine | % | supp | - | 47% | 56% | 60% | 74% | 57% | 54% | 61% | 32% | 48% | 86% | 80% | 81% | 80% | 75% | 78% | 62% | 89% | 79% | 95% | 88% | 94% | 94% | 91% | 90% | 74% | 88% | 69% | 90% | 75% | 63% | 63% | 63% | 69% | 71% | 89% | 79% | 83% | 86% | 68% | 72% | ||||||
63 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the DTP vaccine, aggregated across doses | % | supp | - | 37% | 48% | 55% | 65% | 47% | 46% | 56% | 20% | 36% | 82% | 65% | 79% | 74% | 72% | 72% | 46% | 86% | 73% | 94% | 86% | 89% | 92% | 83% | 89% | 65% | 73% | 61% | 86% | 63% | 50% | 50% | 50% | 57% | 66% | 84% | 64% | 74% | 83% | 63% | 68% | ||||||
64 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the Hib vaccine, aggregated across doses | % | supp | - | 37% | 48% | 55% | 65% | 47% | 46% | 56% | 20% | 36% | 82% | 65% | 79% | 74% | 72% | 72% | 46% | 86% | 73% | 94% | 86% | 89% | 92% | 83% | 89% | 65% | 73% | 61% | 86% | 63% | 50% | 50% | 50% | 57% | 66% | 84% | 64% | 74% | 83% | 63% | 68% | ||||||
65 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the PCV vaccine, aggregated across doses | % | supp | - | 37% | 45% | 54% | 63% | 46% | 44% | 55% | 16% | 36% | 80% | 65% | 78% | 74% | 71% | 69% | 41% | 86% | 71% | 94% | 82% | 87% | 92% | 84% | 87% | 63% | 72% | 58% | 85% | 62% | 49% | 49% | 49% | 55% | 64% | 80% | 63% | 68% | 82% | 61% | 66% | ||||||
66 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the rotavirus vaccine, aggregated across doses | % | supp | - | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||
67 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who received the measles vaccine | % | supp | - | 29% | 35% | 53% | 54% | 39% | 42% | 60% | 18% | 44% | 71% | 58% | 69% | 64% | 63% | 65% | 37% | 76% | 70% | 88% | 76% | 90% | 76% | 85% | 72% | 54% | 69% | 61% | 82% | 54% | 52% | 52% | 52% | 53% | 63% | 77% | 58% | 67% | 81% | 62% | 68% | ||||||
68 | ||||||||||||||||||||||||||||||||||||||||||||||||||
69 | Vaccine coverage for populations under age 5 represented by GBD 2021, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
70 | Proportion of people under age 5 represented in GBD 2021 disease burden estimates who were vaccinated, aggregated across vaccines | % | calc | - | 30% | 37% | 47% | 54% | 38% | 37% | 46% | 16% | 32% | 63% | 54% | 66% | 66% | 56% | 53% | 33% | 74% | 62% | 80% | 73% | 77% | 80% | 73% | 76% | 54% | 66% | 51% | 73% | 53% | 41% | 41% | 41% | 47% | 56% | 70% | 56% | 59% | 71% | 49% | 57% | ||||||
71 | ||||||||||||||||||||||||||||||||||||||||||||||||||
72 | Vaccine efficacy and coverage for older age groups, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||||||||||||||||||||||||||
74 | Effect of vaccination on disease incidence among 5-14-year-olds | |||||||||||||||||||||||||||||||||||||||||||||||||
75 | Proportion of vaccine-preventable disease incidence averted by BCG vaccination among 5-14-year-olds | % | supp | 65% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
76 | Proportion of vaccine-preventable disease incidence averted by DTP vaccination among 5-14-year-olds | % | supp | 64% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
77 | Proportion of vaccine-preventable disease incidence averted by Hib vaccination among 5-14-year-olds | % | supp | 63% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
78 | Proportion of vaccine-preventable disease incidence averted by PCV vaccination among 5-14-year-olds | % | supp | 44% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
79 | Proportion of vaccine-preventable disease incidence averted by rotavirus vaccination among 5-14-year-olds | % | supp | 35% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
80 | Proportion of vaccine-preventable disease incidence averted by measles vaccination among 5-14-year-olds | % | supp | 60% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
81 | ||||||||||||||||||||||||||||||||||||||||||||||||||
82 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by each vaccine | |||||||||||||||||||||||||||||||||||||||||||||||||
83 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the BCG vaccine | % | supp | - | 22% | 15% | 24% | 13% | 17% | 21% | 20% | 22% | 23% | 11% | 15% | 12% | 12% | 9% | 15% | 15% | 10% | 12% | 14% | 13% | 13% | 14% | 14% | 13% | 13% | 9% | 11% | 13% | 13% | 15% | 15% | 15% | 13% | 12% | 13% | 9% | 15% | 13% | 15% | 22% | ||||||
84 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the DTP vaccine | % | supp | - | 13% | 16% | 16% | 19% | 14% | 16% | 19% | 17% | 17% | 11% | 11% | 14% | 19% | 19% | 9% | 15% | 10% | 14% | 10% | 12% | 9% | 11% | 11% | 9% | 19% | 33% | 17% | 9% | 14% | 15% | 15% | 15% | 14% | 11% | 11% | 21% | 10% | 12% | 12% | 15% | ||||||
85 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the Hib vaccine | % | supp | - | 2% | 3% | 2% | 3% | 3% | 2% | 2% | 2% | 2% | 4% | 3% | 4% | 4% | 3% | 3% | 3% | 4% | 4% | 4% | 4% | 4% | 4% | 4% | 4% | 3% | 3% | 3% | 4% | 3% | 3% | 3% | 3% | 4% | 4% | 4% | 3% | 4% | 4% | 3% | 2% | ||||||
86 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the PCV vaccine | % | supp | - | 34% | 41% | 35% | 46% | 48% | 33% | 32% | 32% | 32% | 54% | 49% | 54% | 53% | 40% | 47% | 38% | 57% | 55% | 54% | 57% | 58% | 53% | 60% | 60% | 46% | 39% | 47% | 63% | 50% | 44% | 44% | 44% | 54% | 56% | 56% | 46% | 50% | 57% | 47% | 33% | ||||||
87 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the rotavirus vaccine | % | supp | - | 20% | 17% | 12% | 10% | 13% | 16% | 16% | 16% | 15% | 17% | 16% | 10% | 8% | 22% | 21% | 22% | 13% | 9% | 13% | 9% | 9% | 12% | 7% | 9% | 10% | 10% | 12% | 6% | 13% | 16% | 16% | 16% | 10% | 12% | 10% | 14% | 16% | 8% | 17% | 17% | ||||||
88 | Proportion of deaths from vaccine-preventable causes among unvaccinated 5-14-year-olds that are addressable by the measles vaccine | % | supp | - | 10% | 7% | 11% | 9% | 6% | 12% | 11% | 11% | 11% | 4% | 5% | 7% | 5% | 8% | 4% | 9% | 5% | 6% | 6% | 5% | 7% | 5% | 4% | 4% | 9% | 6% | 9% | 5% | 6% | 7% | 7% | 7% | 5% | 5% | 6% | 7% | 6% | 5% | 6% | 10% | ||||||
89 | ||||||||||||||||||||||||||||||||||||||||||||||||||
90 | Vaccine efficacy, aggregated across vaccines | |||||||||||||||||||||||||||||||||||||||||||||||||
91 | Proportion of vaccine-preventable disease incidence averted by full vaccination among 5-14-year-olds, aggregated across vaccines | % | calc | - | 52% | 51% | 54% | 52% | 51% | 53% | 53% | 53% | 53% | 49% | 50% | 50% | 51% | 50% | 49% | 50% | 49% | 51% | 50% | 50% | 50% | 50% | 50% | 50% | 52% | 53% | 51% | 50% | 50% | 51% | 51% | 51% | 51% | 49% | 50% | 51% | 50% | 50% | 50% | 52% | ||||||
92 | ||||||||||||||||||||||||||||||||||||||||||||||||||
93 | Vaccine coverage for 5-14-year-old populations represented by GBD 2021, aggregated across doses | |||||||||||||||||||||||||||||||||||||||||||||||||
94 | Adjustment for lower vaccine coverage among 5-14-year-olds represented in GBD 2021 disease burden estimates | % | input | -50% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||
95 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the BCG vaccine | % | calc | - | 23% | 28% | 30% | 37% | 29% | 27% | 30% | 16% | 24% | 43% | 40% | 41% | 40% | 38% | 39% | 31% | 44% | 40% | 47% | 44% | 47% | 47% | 45% | 45% | 37% | 44% | 34% | 45% | 38% | 32% | 32% | 32% | 34% | 36% | 44% | 39% | 42% | 43% | 34% | 36% | ||||||
96 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the DTP vaccine, aggregated across doses | % | calc | - | 18% | 24% | 27% | 32% | 23% | 23% | 28% | 10% | 18% | 41% | 32% | 39% | 37% | 36% | 36% | 23% | 43% | 37% | 47% | 43% | 44% | 46% | 42% | 44% | 32% | 37% | 30% | 43% | 31% | 25% | 25% | 25% | 28% | 33% | 42% | 32% | 37% | 41% | 32% | 34% | ||||||
97 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the Hib vaccine, aggregated across doses | % | calc | - | 18% | 24% | 27% | 32% | 23% | 23% | 28% | 10% | 18% | 41% | 32% | 39% | 37% | 36% | 36% | 23% | 43% | 37% | 47% | 43% | 44% | 46% | 42% | 44% | 32% | 37% | 30% | 43% | 31% | 25% | 25% | 25% | 28% | 33% | 42% | 32% | 37% | 41% | 32% | 34% | ||||||
98 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the PCV vaccine, aggregated across doses | % | calc | - | 18% | 23% | 27% | 32% | 23% | 22% | 27% | 8% | 18% | 40% | 33% | 39% | 37% | 36% | 34% | 20% | 43% | 36% | 47% | 41% | 43% | 46% | 42% | 44% | 32% | 36% | 29% | 42% | 31% | 25% | 25% | 25% | 27% | 32% | 40% | 32% | 34% | 41% | 30% | 33% | ||||||
99 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the rotavirus vaccine, aggregated across doses | % | calc | - | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||
100 | Proportion of 5-14-year-olds represented in GBD 2021 disease burden estimates who received the measles vaccine | % | calc | - | 15% | 17% | 27% | 27% | 19% | 21% | 30% | 9% | 22% | 36% | 29% | 34% | 32% | 32% | 32% | 18% | 38% | 35% | 44% | 38% | 45% | 38% | 43% | 36% | 27% | 34% | 31% | 41% | 27% | 26% | 26% | 26% | 27% | 31% | 38% | 29% | 33% | 40% | 31% | 34% | ||||||